Once-daily, oral SGLT2 inhibitor Brenzavvy has been shown to reduce blood sugar and improve glycemic control.
The FDA has approved Brenzavvy (bexagliflozin), an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor. Developed by TheracosBio, Brenzavvy is a SGLT2 inhibitor that is indicated to improve glycemic control in adults with type 2 diabetes. SGLT2 inhibitors are a class of prescription medicines that lower blood sugar by causing the kidneys to remove sugar from the body through urine.
According to the U.S. Centers for Disease Control and Prevention, more than 33 million Americans have type 2 diabetes.
Brenzavvy will be available as 20 mg oral tablets to be taken once daily. The details on its availability and pricing are still in development, a company spokesperson told Formulary Watch.
“As a class of drugs, SGLT2 inhibitors have shown tremendous benefit in treating adults with type 2 diabetes,” Mason Freeman, M.D., director of the Translational Research Center at Massachusetts General Hospital,” said in a press release. “Being involved in all of the clinical trials for Brenzavvy, I am greatly impressed with the efficacy of the drug in reducing blood glucose levels and I believe it is an important addition to the SGLT2 inhibitor class of drugs.”
The FDA approval is based on results from a clinical program that evaluated the safety and efficacy in 23 clinical trials enrolling more than 5,000 adults with type 2 diabetes mellitus. In one phase 2 trial of 288 patients, Brenzavvy was found to be well-tolerated and provided a durable, clinically meaningful improvement in glycemic control over 96 weeks.
Phase 3 studies showed that Brenzavvy significantly reduced hemoglobin A1c and fasting blood sugar after 24 weeks, either as a monotherapy and in combination with metformin. In one phase 3 trial that enrolled 426 patients, Brenzavvy was found noninferior to glimepiride, an oral antidiabetic, in lowering hemoglobin A1c and was associated with significantly fewer hypoglycemic events than glimepiride. In another phase 3 trial of 312 patients, bexagliflozin lowered hemoglobin A1c levels by 0.37% compared with placebo.
Although the therapy is not approved for weight or blood pressure reduction, modest decreases in both weight and systolic blood pressure have been observed in the clinical program.
The most common adverse reactions were female mycotic infections, urinary tract infection and increased urination.
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
FDA Sets Goal Date for Lymphoma Drug Columvi
December 5th 2024The combination of Columvi, gemcitabine and oxaliplatin is the first CD20xCD3 bispecific antibody to show positive results in a randomized diffuse large B-cell lymphoma phase 3 trial. The FDA’s decision is expected by July 20, 2025.
Read More
Diabetes Management & Telehealth with Leslie Kolb
June 11th 2020Association of Diabetes Care and Education Specialists, chief science and practice officer, Leslie Kolb chats with MHE Associate Editor Briana Contreras in MHE's newest podcast Tuning into the C-Suite about diabetes management and how it's affected by the use of telehealth, especially during the current and trying times of the COVID-19 pandemic.
Listen